CTOs on the Move

Inversago Pharma

www.inversago.com

 
A specialized, preclinical-stage biotech company, Inversago Pharma develops new generations of peripherally-restricted cannabinoid-1 receptor (CB1) inverse agonists/ antagonists for the treatment of Prader-Willi Syndrome, diabetes, obesity and other metabolic disorders such as non-alcoholic steatohepatitis (NASH).
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.inversago.com
  • 1 Place Ville-Marie Suite 1670
    Montreal, QC CAN H3B 2B6
  • Phone: N/A

Executives

Name Title Contact Details

Funding

Inversago Pharma raised $35M on 09/08/2020

Similar Companies

US Medical Innovations

US Medical Innovations, LLC is a privately-held FDA registered Plasma Medicine company developing products for Laparoscopic, Robotic and Cancer surgeries.

Mylan Pharmaceuticals Inc

Mylan Inc. (Mylan) and its subsidiaries comprise a global pharmaceutical company that develops, licenses, manufactures, markets and distributes generic, brand and branded generic pharmaceutical products and active pharmaceutical ingredients (API). As of

Array Behavioral Care

Array Behavioral Care (formerly InSight + Regroup) is the nation`s leading clinician-centric virtual psychiatry and therapy practice. Array offers telepsychiatry solutions and services across the continuum of care from hospital to home with its OnDemand Care, Scheduled Care, and AtHome Care divisions. For over 20 years, Array has partnered with hundreds of hospitals and health systems, community healthcare organizations, and payers of all sizes to expand access to care and improve outcomes for underserved individuals, facilities, and communities. As an industry pioneer and established thought leader, Array has helped shape the field, define the standard of care and advocate for improved telepsychiatry-friendly regulations.

PCA Pharmacy

PCA Pharmacy is a Louisville, KY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

NeuroBo Pharmaceuticals

NeuroBo Pharmaceuticals is addressing unmet needs in patients with diabetic neuropathy and Alzheimer’s disease.